NCT05631002

Brief Summary

Fat composition of the spinal tumors is positively correlated with classification and differential diagnosis of benign and malignant tumors.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Aug 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2022

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

November 20, 2022

Completed
10 days until next milestone

First Posted

Study publicly available on registry

November 30, 2022

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

November 30, 2022

Status Verified

August 1, 2022

Enrollment Period

1.3 years

First QC Date

November 20, 2022

Last Update Submit

November 20, 2022

Conditions

Spinal TumorBone Tumor

Outcome Measures

Primary Outcomes (1)

  • Type of tumor

    Pathological diagnosis

    One month before treatment

Study Arms (3)

Patients with benign spinal tumor

Diagnostic Test: Chemical shift encoding-based water-fat MRI

Patients with intermediate spinal tumor

Diagnostic Test: Chemical shift encoding-based water-fat MRI

Patients with malignant spinal tumor

Diagnostic Test: Chemical shift encoding-based water-fat MRI

Interventions

Chemical shift encoding-based water-fat MRIDIAGNOSTIC_TEST

Chemical shift encoding-based water-fat magnetic resonance imaging (MRI): a non-invasive method

Patients with benign spinal tumorPatients with intermediate spinal tumorPatients with malignant spinal tumor

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults with spinal tumors

You may qualify if:

  • Pathological biopsy of a patient with diagnosed spinal tumor lesion, and preoperative examination Chemical shift encoding-based water-fat MRI was performed.

You may not qualify if:

  • Recurrent neoplasms; Lesion diameter \< 1 cm; Poor image quality.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University third hospital

Beijing, Beijing Municipality, 100089, China

RECRUITING

MeSH Terms

Conditions

Spinal Cord NeoplasmsBone Neoplasms

Condition Hierarchy (Ancestors)

Central Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsSpinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesBone DiseasesMusculoskeletal Diseases

Study Officials

  • Ning Lang

    Peking University Third Hospital

    STUDY CHAIR

Central Study Contacts

Qizheng Wang

CONTACT

13161593501wangqizheng96@163.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 20, 2022

First Posted

November 30, 2022

Study Start

August 1, 2022

Primary Completion

December 1, 2023

Study Completion

December 31, 2023

Last Updated

November 30, 2022

Record last verified: 2022-08

Locations

CN(1)